[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-373052-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-373052-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","management-of-vasomotor-symptoms-in-cancer-patients","Management of Vasomotor Symptoms in Cancer Patients","","Many cancer treatments reduce sex hormone levels, which can trigger vasomotor symptoms (VMS) such as hot flashes. VMS can worsen quality of life and undermine tolerability, leading to suboptimal adherence to cancer therapy. Hormone therapy that raises estradiol or testosterone is the standard option, yet it is commonly contraindicated in hormone-sensitive cancers. Nonhormone agents with limited-to-moderate efficacy and possible side effects are also used. This narrative review evaluates evidence for multiple treatments, including fezolinetant, and addresses patient-specific considerations by cancer type and age.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/management-of-vasomotor-symptoms-in-cancer-patients/373052/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/management-of-vasomotor-symptoms-in-cancer-patients/373052.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do cancer patients develop vasomotor symptoms such as hot flashes?","Question",{"text":63,"@type":64},"Many cancer treatments can lower sex hormones like testosterone and estradiol, which are linked to vasomotor symptoms including hot flashes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is hormone therapy often not suitable for some cancer patients?",{"text":68,"@type":64},"Hormone therapy that increases estradiol or testosterone is generally contraindicated in patients with hormone-sensitive cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review emphasize about managing VMS in different patient populations?",{"text":72,"@type":64},"It highlights the need for timely identification and management of symptoms, and it notes special considerations across cancer types (e.g., breast, prostate) and age groups (e.g., older adults).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},373052,1790217274,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Management of vasomotor symptoms in cancer patients  \nLing Zhu1,2,*,, Tammy T. Hshieh3, Tara K. Iyer4, Alicia K. Morgans5, Ole-Petter R. Hamnvik2,  \n1Department of Endocrinology, Singapore General Hospital, Singapore 169856  \n2Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, United States  \n3Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, United States  \n4Menopause and Midlife Clinic, Division of Women’s Health, Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02215, United States  \n5Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States  \n*Corresponding author: Ling Zhu, Department of Endocrinology, Singapore General Hospital, 20 College Road, Singapore 169856 ([gmszlin@nus.edu.sg](gmszlin@nus.edu.sg)) .  \nAbstract  \nMany cancer treatments can lead to reduced levels of sex hormones, which in turn may cause vasomotor symptoms (VMS) such as hot flashes. These symptoms are associated with impaired quality of life, as well as suboptimal tolerability of and adherence to cancer treatment. Hormone therapy, performed by increasing estradiol or testosterone levels, is the gold standard for treatment of VMS. However, this approach is generally contraindicated in patients with hormone-sensitive cancers. Nonhormone agents with low to moderate efficacy in controlling VMS are available, but their use may be limited by side effects and tolerability. In this narrative review, the approach to VMS in cancer patients will be discussed. The evidence for various treatment options, including novel agents such as fezolinetant that target the hypothalamic thermoregulatory pathway, will be evaluated. Finally, special considerations in different patient populations based on cancer types (eg, breast, prostate) and age groups (eg, older adults) will be explored.  \nKey words: hot flashes; menopause; breast cancer; prostate cancer; cancer survivors.  \nImplications for Practice  \nOptimal management in cancer survivorship requires timely identification and management of symptoms. Hormone therapy is the gold standard treatment for VMS but is contraindicated in hormone-sensitive cancers. There is growing evidence demonstrating the efficacy of nonhormone options. While generally well tolerated by many, these agents can be associated with side effects that cancer patients maybe particularly susceptible to. Encouragingly, emerging drug targets have enabled the development of novel pharmacologic treatments, thereby expanding treatment options for cancer patients with VMS. A comprehensive understanding of these therapeutic agents would enable health care providers to plan effective treatment strategies for cancer survivors experiencing VMS.  \nIntroduction  \nAn increasing number of people are living with a diagnosis of cancer, due to earlier diagnosis and improved survival of many cancer types.1 In many cases, this means that patients are receiving cancer treatments for longer, or living with longterm side effects of cancer treatments. As a result, there is a growing focus on management of side effects of cancer treatment. One common consequence of many cancer treatments is hypogonadism, marked by a reduced level of sex hormones such as testosterone and estradiol. This can occur as a primary treatment goal in the setting of hormone-responsive cancers, as a side effect during gonadotoxic chemotherapy, or as a result of the underlying cancer itself.2,3 Hypogonadismis frequently associated with vasomotor symptoms (VMSs), such as hot flashes. Traditionally, VMSs are regarded as hallmark symptoms of menopause in women entering the end of reproductive years.4 In the general population, up to 79% of menopausal women and 33% of aging men are affected by  \nVMS.5,6 In menopausal women, VMS have a median duration of 7 years, or even longer in those with early onset of VMS, and/or African American","cbCairpDMW5laTmg","https://ap.wps.com/l/cbCairpDMW5laTmg","pdf",1256151,16,"English","# Abstract\n# Implications for Practice\n# Introduction\n## Vasomotor symptoms in the cancer survivorship setting\n## Hormone therapy constraints in hormone-sensitive cancers\n# (Review content continues beyond provided text)","[{\"question\":\"Why do cancer patients develop vasomotor symptoms such as hot flashes?\",\"answer\":\"Many cancer treatments can lower sex hormones like testosterone and estradiol, which are linked to vasomotor symptoms including hot flashes.\"},{\"question\":\"Why is hormone therapy often not suitable for some cancer patients?\",\"answer\":\"Hormone therapy that increases estradiol or testosterone is generally contraindicated in patients with hormone-sensitive cancers.\"},{\"question\":\"What does the review emphasize about managing VMS in different patient populations?\",\"answer\":\"It highlights the need for timely identification and management of symptoms, and it notes special considerations across cancer types (e.g., breast, prostate) and age groups (e.g., older adults).\"}]","Management of Vasomotor Symptoms in Cancer Patients | PDF",1790196500]